Study analysis · Molecular and Cellular Biochemistry · 1998
A sugar-like molecule blocks glucose processing in test tubes—but only living pancreas cells actually stop responding. Why?
D-mannoheptulose blocks the first step of sugar breakdown in liver and saliva gland samples, but only stops whole pancreas islets from releasing insulin, not whole saliva gland cells.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done in test tubes and cells, not people or animals. It shows how a sugar-like substance affects glucose processing in specific lab conditions. We can't say it would work the same way in humans.
What’s the bottom line?
Scientists tested D-mannoheptulose, a molecule used to block sugar processing. They looked at liver, saliva gland cells, and pancreas islets to see how it stops glucose from being used. It blocked glucose processing in test-tube pieces from all tissues, but only actually stopped living pancreas islets from responding to glucose. It did not stop living saliva gland cells.
How strong is this study?
We only have a short summary, not the full details, so we can't check if the experiments were done well. The results might be interesting, but without more information, we should be careful about trusting them completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 53 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. In vitro study, no randomization, no blinding, abstract only. Cannot establish cause-effect relationships in humans or animals.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were identified in the provided text.
The provided text is an abstract without a conflict of interest statement, funding disclosure, or author affiliations. No COI or funding concerns can be assessed from this excerpt.
Key takeaways
- 01
D-mannoheptulose blocked glucose phosphorylation in liver and parotid homogenates with mixed inhibition (mostly non-competitive in liver, competitive in parotid).
- 02
It also blocked hexose phosphorylation in parotid and islet homogenates.
- 03
In intact cells, it suppressed glucose metabolism and insulin release only in pancreatic islets, not parotid cells.
- 04
No effect sizes or numbers were reported in the abstract.
- 05
This is an in vitro lab study, so there is no human absolute risk or cases-per-1,000 number.
- 06
The abstract does not report effect sizes or absolute risks.
- 07
It suggests the molecule's effect depends on whether it can get inside cells, not just whether it can block enzymes in a test tube.
Surprising findings
- D-mannoheptulose inhibited hexose phosphorylation in parotid cell homogenates but did not adversely affect D-glucose catabolism in intact parotid cells.You'd expect an enzyme inhibitor that works in broken cells to also work in whole cells, but it didn't for parotid cells.
- The inhibition type was mixed: predominantly non-competitive in liver homogenates and competitive in parotid homogenates.D-mannoheptulose is described as a competitive inhibitor tool, but this study found tissue-dependent mixed kinetics.
Practical takeaways
No actionable human takeaway from this abstract; it is an in vitro mechanistic study with no reported effect sizes, sample sizes, or human data.
Findings are from homogenates and isolated cells; cannot be extrapolated to human health or blood sugar control. Full methodology not available.
low confidenceWhy this study matters
Not just competitive: mixed inhibition
D-mannoheptulose is used as a competitive inhibitor of glucose phosphorylation in pancreatic islet B-cells. This study found mixed inhibition: predominantly non-competitive in liver homogenates and competitive in parotid homogenates. No effect sizes or p-values were reported in the abstract.
It challenges the textbook assumption that this tool works the same way in all tissues.
Test tube vs living cells mismatch
The heptose efficiently inhibited hexose phosphorylation in both parotid cell and islet homogenates. But in intact cells, it suppressed metabolic and functional responses to D-glucose only in pancreatic islets, not in parotid cells.
It shows that blocking an enzyme in a test tube doesn't always translate to blocking a whole living cell.
Intracellular availability may be key
Authors suggest intracellular transport and availability of the heptose may interfere with its antagonistic action on D-glucose metabolism. No transport data or effect sizes were reported in the abstract.
It hints that getting a drug inside a cell matters as much as its enzyme-blocking ability.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested D-mannoheptulose, a molecule used to block sugar processing. They looked at liver, saliva gland cells, and pancreas islets to see how it stops glucose from being used. It blocked glucose processing in test-tube pieces from all tissues, but only actually stopped living pancreas islets from responding to glucose. It did not stop living saliva gland cells.
Research results
D-mannoheptulose blocked glucose phosphorylation in liver and parotid homogenates with mixed inhibition (mostly non-competitive in liver, competitive in parotid). It also blocked hexose phosphorylation in parotid and islet homogenates. In intact cells, it suppressed glucose metabolism and insulin release only in pancreatic islets, not parotid cells. No effect sizes or numbers were reported in the abstract.
What this means - more context
This is an in vitro lab study, so there is no human absolute risk or cases-per-1,000 number. The abstract does not report effect sizes or absolute risks. It suggests the molecule's effect depends on whether it can get inside cells, not just whether it can block enzymes in a test tube.
To better understand the mode of action of D-mannoheptulose as an inhibitor of D-glucose phosphorylation, metabolism, and functional effects by comparing liver, parotid cells, and pancreatic islets.
D-mannoheptulose inhibited D-glucose phosphorylation with mixed kinetics: predominantly non-competitive in liver homogenates and competitive in parotid homogenates. It efficiently inhibited hexose phosphorylation in both parotid cell and islet homogenates, but suppressed metabolic and functional responses to D-glucose only in intact pancreatic islets, not in parotid cells. The authors suggest intracellular transport and availability of the heptose may affect its antagonistic action. No effect sizes, p-values, or sample sizes were reported in the abstract.
Methods Used
In vitro experiments using liver, parotid cells, and pancreatic islet homogenates; intact parotid cells and pancreatic islets; measured D-glucose phosphorylation, metabolism, and glucose-stimulated insulin release over large concentration ranges of heptose and hexose. Methodology details not available in abstract.
Main Finding
D-mannoheptulose produced a mixed type of inhibition of D-glucose phosphorylation, predominantly non-competitive in liver homogenates and competitive in parotid homogenates. Despite inhibiting hexose phosphorylation in parotid cell and islet homogenates, it suppressed metabolic and functional responses to D-glucose only in pancreatic islets, while failing to adversely affect D-glucose catabolism in parotid cells. No effect sizes reported in abstract.
Confidence Level
Limited - based on abstract only, full methodology not available. No effect sizes, p-values, sample sizes, or full text; experimental rigor cannot be verified.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Abstract-only summary; no sample sizes, effect sizes, or statistical details reported
- •In vitro mechanistic study; findings may not translate directly to human physiology
Surprising Findings
D-mannoheptulose inhibited hexose phosphorylation in parotid cell homogenates but did not adversely affect D-glucose catabolism in intact parotid cells.
You'd expect an enzyme inhibitor that works in broken cells to also work in whole cells, but it didn't for parotid cells.
Practical Takeaways
No actionable human takeaway from this abstract; it is an in vitro mechanistic study with no reported effect sizes, sample sizes, or human data.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 53 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
In Vitro Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study was done in test tubes and cells, not people or animals. It shows how a sugar-like substance affects glucose processing in specific lab conditions. We can't say it would work the same way in humans.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Examined multiple tissue types (liver, parotid, islets)
- Used concentration-response ranges
- Investigated both phosphorylation and functional effects
Weaknesses
- Full methodology not available - based on abstract only
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested D-mannoheptulose, a molecule used to block sugar processing. They looked at liver, saliva gland cells, and pancreas islets to see how it stops glucose from being used. It blocked glucose processing in test-tube pieces from all tissues, but only actually stopped living pancreas islets from responding to glucose. It did not stop living saliva gland cells.
Research results
D-mannoheptulose blocked glucose phosphorylation in liver and parotid homogenates with mixed inhibition (mostly non-competitive in liver, competitive in parotid). It also blocked hexose phosphorylation in parotid and islet homogenates. In intact cells, it suppressed glucose metabolism and insulin release only in pancreatic islets, not parotid cells. No effect sizes or numbers were reported in the abstract.
What this means - more context
This is an in vitro lab study, so there is no human absolute risk or cases-per-1,000 number. The abstract does not report effect sizes or absolute risks. It suggests the molecule's effect depends on whether it can get inside cells, not just whether it can block enzymes in a test tube.
To better understand the mode of action of D-mannoheptulose as an inhibitor of D-glucose phosphorylation, metabolism, and functional effects by comparing liver, parotid cells, and pancreatic islets.
D-mannoheptulose inhibited D-glucose phosphorylation with mixed kinetics: predominantly non-competitive in liver homogenates and competitive in parotid homogenates. It efficiently inhibited hexose phosphorylation in both parotid cell and islet homogenates, but suppressed metabolic and functional responses to D-glucose only in intact pancreatic islets, not in parotid cells. The authors suggest intracellular transport and availability of the heptose may affect its antagonistic action. No effect sizes, p-values, or sample sizes were reported in the abstract.
Methods Used
In vitro experiments using liver, parotid cells, and pancreatic islet homogenates; intact parotid cells and pancreatic islets; measured D-glucose phosphorylation, metabolism, and glucose-stimulated insulin release over large concentration ranges of heptose and hexose. Methodology details not available in abstract.
Main Finding
D-mannoheptulose produced a mixed type of inhibition of D-glucose phosphorylation, predominantly non-competitive in liver homogenates and competitive in parotid homogenates. Despite inhibiting hexose phosphorylation in parotid cell and islet homogenates, it suppressed metabolic and functional responses to D-glucose only in pancreatic islets, while failing to adversely affect D-glucose catabolism in parotid cells. No effect sizes reported in abstract.
Confidence Level
Limited - based on abstract only, full methodology not available. No effect sizes, p-values, sample sizes, or full text; experimental rigor cannot be verified.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Abstract-only summary; no sample sizes, effect sizes, or statistical details reported
- •In vitro mechanistic study; findings may not translate directly to human physiology
Surprising Findings
D-mannoheptulose inhibited hexose phosphorylation in parotid cell homogenates but did not adversely affect D-glucose catabolism in intact parotid cells.
You'd expect an enzyme inhibitor that works in broken cells to also work in whole cells, but it didn't for parotid cells.
Practical Takeaways
No actionable human takeaway from this abstract; it is an in vitro mechanistic study with no reported effect sizes, sample sizes, or human data.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 53 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
In Vitro Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study was done in test tubes and cells, not people or animals. It shows how a sugar-like substance affects glucose processing in specific lab conditions. We can't say it would work the same way in humans.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Examined multiple tissue types (liver, parotid, islets)
- Used concentration-response ranges
- Investigated both phosphorylation and functional effects
Weaknesses
- Full methodology not available - based on abstract only
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
We only have a short summary, not the full details, so we can't check if the experiments were done well. The results might be interesting, but without more information, we should be careful about trusting them completely.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 53 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. In vitro study, no randomization, no blinding, abstract only. Cannot establish cause-effect relationships in humans or animals.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were identified in the provided text.
The provided text is an abstract without a conflict of interest statement, funding disclosure, or author affiliations. No COI or funding concerns can be assessed from this excerpt.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Thomas DeLauer cite this study, drawing 1 claim from it.
- Indication only
Weak evidence — fewer than 20 studies, so treat this as a starting point, not a fact.
Evidence
Authored by
4 researchersIf this is your work, this is how we attribute it on Fit Body Science. Olivier Scruel is listed as the lead author.